Treatment outcome of localized prostate cancer by 70 Gy hypofractionated intensity-modulated radiotherapy with a customized rectal balloon |
Kim, Hyunjung
(Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine)
Kim, Jun Won (Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine) Hong, Sung Joon (Department of Urology, Yonsei Cancer Center, Yonsei University College of Medicine) Rha, Koon Ho (Department of Urology, Yonsei Cancer Center, Yonsei University College of Medicine) Lee, Chang-Geol (Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine) Yang, Seung Choul (Department of Urology, Yonsei Cancer Center, Yonsei University College of Medicine) Choi, Young Deuk (Department of Urology, Yonsei Cancer Center, Yonsei University College of Medicine) Suh, Chang-Ok (Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine) Cho, Jaeho (Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine) |
1 | Symon Z, Griffith KA, McLaughlin PW, Sullivan M, Sandler HM. Dose escalation for localized prostate cancer: substantial benefit observed with 3D conformal therapy. Int J Radiat Oncol Biol Phys 2003;57:384-90. DOI ScienceOn |
2 | Pollack A, Hanlon A, Horwitz EM, Feigenberg S, Uzzo RG, Price RA. Radiation therapy dose escalation for prostate cancer: a rationale for IMRT. World J Urol 2003;21:200-8. DOI ScienceOn |
3 | Zelefsky MJ, Fuks Z, Hunt M, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001;166:876-81. DOI ScienceOn |
4 |
Oliveira SM, Teixeira NJ, Fernandes L. What do we know about the |
5 | Daş u A. Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials? Clin Oncol (R Coll Radiol) 2007;19:289-301. DOI ScienceOn |
6 | Brenner DJ. Fractionation and late rectal toxicity. Int J Radiat Oncol Biol Phys 2004;60:1013-5. DOI ScienceOn |
7 | Wachter S, Gerstner N, Dorner D, et al. The influence of a rectal balloon tube as internal immobilization device on variations of volumes and dose-volume histograms during treatment course of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2002;52:91-100. DOI ScienceOn |
8 | Teh BS, McGary JE, Dong L, et al. The use of rectal balloon during the delivery of intensity modulated radiotherapy (IMRT) for prostate cancer: more than just a prostate gland immobilization device? Cancer J 2002;8:476-83. DOI ScienceOn |
9 | Cho JH, Lee CG, Kang DR, et al. Positional reproducibility and effects of a rectal balloon in prostate cancer radiotherapy. J Korean Med Sci 2009;24:894-903. DOI ScienceOn |
10 | Sylvester JE, Blasko JC, Grimm PD, Meier R, Malmgren JA. Tenyear biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience. Int J Radiat Oncol Biol Phys 2003;57:944-52. DOI ScienceOn |
11 | Roach M 3rd, Marquez C, Yuo HS, et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1994;28:33-7. DOI ScienceOn |
12 | Thames HD, Kuban D, Levy LB, et al. The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995. Radiother Oncol 2010;96:6-12. DOI ScienceOn |
13 | Kupelian PA, Thakkar VV, Khuntia D, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes. Int J Radiat Oncol Biol Phys 2005;63:1463-8. DOI ScienceOn |
14 | Martin JM, Rosewall T, Bayley A, et al. Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 2007;69:1084-9. DOI ScienceOn |
15 | Faria S, Dal Pra A, Cury F, et al. Treating intermediate-risk prostate cancer with hypofractionated external beam radiotherapy alone. Radiother Oncol 2011;101:486-9. DOI ScienceOn |
16 | Fonteyne V, Soete G, Arcangeli S, et al. Hypofractionated highdose radiation therapy for prostate cancer: long-term results of a multi-institutional phase II trial. Int J Radiat Oncol Biol Phys 2012;84:e483-90. DOI ScienceOn |
17 | Leborgne F, Fowler J, Leborgne JH, Mezzera J. Later outcomes and alpha/beta estimate from hypofractionated conformal three-dimensional radiotherapy versus standard fractionation for localized prostate cancer. Int J Radiat Oncol Biol Phys 2012;82:1200-7. DOI ScienceOn |
18 | Arcangeli S, Strigari L, Gomellini S, et al. Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012;84:1172-8. DOI ScienceOn |
19 | Pollack A, Walker G, Horwitz EM, et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol 2013;31:3860-8. DOI ScienceOn |
20 | Dearnaley D, Syndikus I, Sumo G, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol 2012;13:43-54. DOI ScienceOn |
21 | Coote JH, Wylie JP, Cowan RA, Logue JP, Swindell R, Livsey JE. Hypofractionated intensity-modulated radiotherapy for carcinoma of the prostate: analysis of toxicity. Int J Radiat Oncol Biol Phys 2009;74:1121-7. DOI ScienceOn |
22 | Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 2007;68:1424-30. DOI ScienceOn |
23 | Hoffman KE, Voong KR, Pugh TJ, et al. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. Int J Radiat Oncol Biol Phys 2014;88:1074-84. DOI ScienceOn |
24 | Patel N, Faria S, Cury F, et al. Hypofractionated radiation therapy (66 Gy in 22 fractions at 3 Gy per fraction) for favorable-risk prostate cancer: long-term outcomes. Int J Radiat Oncol Biol Phys 2013;86:534-9. DOI ScienceOn |
25 | Aizer AA, Yu JB, McKeon AM, Decker RH, Colberg JW, Peschel RE. Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 2009;75:1344-9. DOI ScienceOn |
26 | Arcangeli G, Fowler J, Gomellini S, et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2011;79:1013-21. DOI ScienceOn |
27 | Lund JA, Kaasa S, Wibe A, Widmark A, Fransson P. Late radiation effects to the rectum and anus after treatment for prostate cancer; validity of the LENT/SOMA score. Acta Oncol 2013;52:727-35. DOI ScienceOn |
28 | Smeenk RJ, Louwe RJ, Langen KM, et al. An endorectal balloon reduces intrafraction prostate motion during radiotherapy. Int J Radiat Oncol Biol Phys 2012;83:661-9. DOI ScienceOn |
29 | Seaward SA, Weinberg V, Lewis P, Leigh B, Phillips TL, Roach M 3rd. Identification of a high-risk clinically localized prostate cancer subgroup receiving maximum benefit from wholepelvic irradiation. Cancer J Sci Am 1998;4:370-7. |
30 | Lawton CA, DeSilvio M, Roach M 3rd, et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 2007;69:646-55. DOI ScienceOn |
31 | Pommier P, Chabaud S, Lagrange JL, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 2007;25:5366-73. DOI ScienceOn |
32 | Asbell SO, Martz KL, Shin KH, et al. Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOG #77-06, a phase III study for T1BN0M0 (A2) and T2N0M0 (B) prostate carcinoma. Int J Radiat Oncol Biol Phys 1998;40:769-82. DOI ScienceOn |
33 | Mantini G, Tagliaferri L, Mattiucci GC, et al. Effect of whole pelvic radiotherapy for patients with locally advanced prostate cancer treated with radiotherapy and long-term androgen deprivation therapy. Int J Radiat Oncol Biol Phys 2011;81:e721-6. DOI ScienceOn |
![]() |